5th ALS Drug Development Summit 2026

Memo

Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity and Restore Hope in a More Transformative Wave of ALS and FTD Therapies. Uniting ALS Biotech, Pharma and Academia to Accelerate the Next Generation of ALS and FTD Therapeutics. Strategic moves across the sector-from Eli Lilly's Alchemab-backed ALS expansion to BMS and insistro's genetically driven collaboration and Clene Nanomedicine's regulatory-stage program-underscore the ALS community’s continued commitment to advancing impactful therapies, even in the face of clinical setbacks. With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working in ALS, and a global ALS market projected to grow from USD 667.3M in 2023 to USD 987.6M by 2030, confidence is returning. Learnings, fuelled by stronger mechanistic hypotheses, and more resilient translational strategies, spanning TDP 43 loss and gain of function biology, cryptic exon regulation, neuroinflammatory pathways, and human relevant iPSC and 3D models, the ALS community is leveraging these lessons to build smarter, more predictive programs. Uniting 100+ senior experts across discovery, translational research, clinical development, regulatory science, investment, and patient advocacy, 30+ speakers from AbbVie, AskBio, Biogen, Eli Lilly, Novartis, QurAlis, Prilenia Therapeutics, Mitsubishi Tanabe Pharma, uniQure, ROME Therapeutics, Everything ALS, Sanofi, and more, this is the definitive forum restoring hope across the ALS and FTD community. URLs:Tickets: https://go.evvnt.com/3463680-2?pid=5569Brochure: https://go.evvnt.com/3463680-3?pid=5569 Date and Time: On Tue, 02 Jun 2026 08:00 - Thu, 04 Jun 2026 17:00 Venue Details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Industry Pricing - Conference + Workshop Day: USD 3697.00,Industry Pricing - Conference Only: USD 2699.00,Service Provider Pricing - Conference + Workshop Day: USD 4597.00,Service Provider Pricing - Conference Only: USD 3399.00,Academic Pricing - Conference + Workshop Day: USD 2997.00,Academic Pricing - Conference Only: USD 2299.00 Speakers: Arti Patel, Principal Scientist, Neuroscience and Program Lead, Novartis, Francisca Martinez-Raub, Director, Eli Lilly, Joel Schwartz, Director, Scientific Digital Biomarkers Neuroscience, Bristol Myers Squibb, Joyce Lo, Associate Director, Biogen, Kelly Glajch, Scientific Director, Rare NeurologyNeuroscience Therapeutic Area Unit, Takeda, Ivan NyarkoDanquah, Postdoctoral Fellow, Sanofi, Makoto Tamura, Executive Director of NeuroDiscovery Lab, Tanabe Pharma America , Murali Gopalakrishnan, Global Head, Neuroscience Search and Evaluation, Corporate Strategy Officer, AbbVie, Yea Jin Kaeser-Woo, Senior Director, Eli Lilly, Yunfeng Huang, Principal Scientist, Biogen, Christopher Shaw, Chief Scientific Officer and Clinical Advisor, AviadoBio, George Apostol, Head of Clinical Development, UniQure, Irina Antonijevic, Chief Medical Officer Trace, Neuroscience, Javier San Martin, Chief Medical Officer, LeonaBio, Mansuo Lu Shannon, Chief Scientific Officer, Ask Bio, Michael Hayden, Chief Executive Officer, Prilenia, Michael Thurn, Chief Executive Officer, Neurizon, Sandy Hinkley, Vice President, Head of Discovery, QurAlis, Sarah Knutson, Executive Director, Early Discovery, ROME Therapeutics, Christian Rubio, Executive Director, Everything ALS, Eloise Jarvis, Senior Researcher, Beacon Research Operations, Hanxiong (Bear) Zhang, Principal, RA Capital Management, Colin Hovingay, Vice President of Rare and Orphan Diseases, Critical Path Institute, John Replogle, Director, National Institutes of Health (NIH), Philip C. Wong, Professor of Pathology, John Hopkins Medicine, Ruth Chia, Staff Scientist, National Institutes of Health (NIH), Ignazio Di Giovanna, Vice President, Scientific Affairs, Neurology Evestia, Clinical , Massimiliano Bianchi, Founder, President and Chief Executive Officer, Ulysses Neuroscience, Matthew Mandeville, Senior Business Development Manager, BrainXell